Immune features in tumors and blood that affect responses to anti‑GD2 therapy for neuroblastoma
Tumor and host immune signatures associated with patient outcomes to GD2 chemoimmunotherapy in neuroblastoma
Researchers will look at immune cells in tumors and blood from children with high‑risk neuroblastoma to find signs that predict how well anti‑GD2 chemoimmunotherapy works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11129674 on NIH RePORTER |
What this research studies
This project analyzes tumor tissue and blood collected from children enrolled in a large pediatric clinical trial to find immune patterns linked to better or worse outcomes with anti‑GD2 chemoimmunotherapy. Scientists will use single‑cell genomics, protein profiling, mass cytometry, and lab tests of immune cell killing to map tumor and blood immune cells before and after treatment. They will also examine inherited genetic differences and early‑life exposure information to see what shapes a child's immune readiness. By combining these data, the team hopes to identify biomarkers of response or resistance that could inform future treatment choices.
Who could benefit from this research
Good fit: Ideal candidates are children with newly diagnosed high‑risk neuroblastoma who received GD2‑directed chemoimmunotherapy (such as participants in the COG ANBL2131 trial).
Not a fit: Children with low‑risk neuroblastoma or those who did not receive GD2‑directed therapy are unlikely to get direct benefits from this specific project.
Why it matters
Potential benefit: If successful, this work could help doctors predict which children are most likely to benefit from anti‑GD2 therapy and tailor treatments to improve outcomes.
How similar studies have performed: Prior studies have linked NK cell activity and tumor immune composition to antibody therapy outcomes, but combining single‑cell, proteomic, functional, and genetic data across a Phase III trial is relatively novel.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Goldsmith, Kelly C — Emory University
- Study coordinator: Goldsmith, Kelly C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.